Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 10/20 | 0.59 |
| ▸ | KCNQ2 | O43526 | 10/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 5/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.42 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794774 | 1.00 | KCNQ3 (0.59) | KCNQ3KCNQ2MAPTL3MBTL1AKT1 | |
| SCHEMBL971475 | 0.83 | KCNQ3 (0.68) | KCNQ3KCNQ2MAPTL3MBTL1AKT1 | |
| SCHEMBL30796083 | 0.83 | KCNQ3 (0.68) | KCNQ3KCNQ2MAPTL3MBTL1AKT1 | |
| SCHEMBL30795610 | 0.83 | KCNQ3 (0.46) | KCNQ3KCNQ2MAPTL3MBTL1AKT1 | |
| SCHEMBL971362 | 0.83 | KCNQ3 (0.46) | KCNQ3KCNQ2MAPTL3MBTL1AKT1 | |
| SCHEMBL30794550 | 0.78 | KCNQ2 (0.60) | KCNQ3KCNQ2MAPTL3MBTL1 | |
| SCHEMBL2439684 | 0.78 | KCNQ2 (0.60) | KCNQ3KCNQ2MAPTL3MBTL1 | |
| SCHEMBL23854549 | 0.77 | KIF18A (0.52) | KCNQ3KCNQ2MAPTAKT1PIK3CD | |
| SCHEMBL970263 | 0.77 | KCNQ2 (0.56) | KCNQ3KCNQ2MAPTL3MBTL1AKT1 | |
| SCHEMBL30824695 | 0.77 | KCNQ2 (0.56) | KCNQ3KCNQ2MAPTL3MBTL1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298766-B1 | Pharmaceutical formulations comrpising a substituted pyridine derivative | LUNDBECK & CO AS H (DK) | 2013-09-18 | — | — | EP | claimed |
| US-8299071-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | claimed |
| EP-2298766-A1 | Substituted pyridine derivatives | H. Lundbeck A/S (DK) | 2011-03-23 | — | — | EP | claimed |
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-01-06 | — | — | US | claimed |
| US-7812020-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2010-10-12 | — | — | US | claimed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| US-20080318953-A1 | Substituted Pyridine Derivatives | H. LUNDBECK A/S (DK) | 2008-12-25 | — | — | US | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2298766-B1 | Pharmaceutical formulations comrpising a substituted pyridine derivative | LUNDBECK & CO AS H (DK) | 2013-09-18 | — | — | EP | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| US-8299071-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | disclosed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | disclosed |
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| US-20080318953-A1 | Substituted Pyridine Derivatives | H. LUNDBECK A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| EP-1983974-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| EP-1861394-A1 | SUBSTITUTED PYRIDINE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
| WO-2006092143-A1 | SUBSTITUTED PYRIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | KCNQ4, KCNQ5, KCNQ1 | KCNQ3 4/4885KCNQ2 5/4885MAPT 1786/4885 |
| US-20080318953-A1 | Substituted Pyridine Derivatives | KCNQ2, KCNQ1, KCNQ5 | KCNQ3 5/4885KCNQ2 1/4885MAPT 1188/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | KCNQ3 4/4885KCNQ2 1/4885MAPT 1260/4885 |
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | KCNQ2, KCNQ1, KCNQ5 | KCNQ3 5/4885KCNQ2 1/4885MAPT 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.